Latest news with #Malvern
New York Times
4 days ago
- Automotive
- New York Times
The Appeal of the Classic-Looking Morgan
Chevrolet wrings a lot of mileage out of the fact that its Suburban holds the record for continuous production of any vehicle model. Ninety years is impressive for any nameplate. However, during that time, the Suburban has been produced in 12 different generations, and if it were possible to bear less than zero resemblance to something, one could say that about the current generation of Suburban in relation to the 1935 original. The two vehicles are far from twins. The Morgan Motor Company of Malvern, England, on the other hand, released its sports car, the 4/4, in 1936, a year after the Suburban, and the design has not changed that radically. The boutique manufacturer's current model, the Plus Four, still bears a resemblance to its ancestor, and in spite of any import tariff, there's a six-month waiting list to get one of these hand-built cars. And as collectibles, the cars, which start at about $85,000 new, seem to hold their value compared with some other old British brands. In two online auctions this year, for example, Morgan prices hit $55,000 (for a 2001 model with 25,000 miles) and $60,000 (for a 2005 roadster with one owner). 'Values of older Morgans have increased about 13 percent over the last 10 years' said Andrew Newton, senior auction editor for the automotive lifestyle brand Hagerty. 'Values haven't increased with the market in general, but Morgans are doing better than cars from defunct British sports car brands like Triumph and Austin-Healey.' Want all of The Times? Subscribe.
Yahoo
4 days ago
- Business
- Yahoo
Vanguard Made a Single Acquisition. Now, It's Getting Sued
Vanguard made its first acquisition in 2021, but by the looks of it, it may just be the last. The Malvern, Pennsylvania-based firm is now facing a lawsuit stemming from the purchase of JustInvest, one of a handful of direct indexing platforms that were all the rage back in the early 2020s. The complaint alleges the world's second-largest money manager acted in bad faith post-sale by thwarting certain business deals that would have led to payouts for JustInvest founders and shareholders. Even today, Vanguard investors aren't able to use the service, which was rebranded Vanguard Personalized Indexing Management, nor can the firm's in-house advisors, according to Jeff DeMaso, editor of the newsletter the Independent Vanguard Advisor. So, why the acquisition in the first place? 'Perhaps it was a move to defend the firm against the risk that direct indexing would replace index mutual funds and ETFs,' DeMaso said. 'If that was the goal, sure, mission accomplished. But that's a low hurdle.' READ ALSO: Defense ETFs Surge Amid Wartime Buildups and Referrals Are Still King, Even In the Era of AI Full Court Press The suit alleges that Vanguard blocked deals that would have led to performance payments, which represented a 'large share' of compensation to JustInvest's founders. In one instance, JustInvest was close to landing $900 million in assets but Vanguard management allegedly put the kibosh on the deal without an explanation. Before the acquisition, however, Vanguard insisted there would be 'lines out the door' for their direct indexing service and that it could help bring in $1 billion in assets to JustInvest on Day 1 alone, according to the complaint filed in Delaware Chancery Court. 'Indeed, before the merger closed, Vanguard expressed concerns that the security-holders would earn the full performance payments under the agreement too quickly,' the suit said. The complaint also alleges the three founders — Jonathan Hudacko, Vijay Rao, and Alan Cummings — were terminated last year without cause in retaliation for raising concerns. Vanguard declined to comment. Direct Hit. Who can forget when direct indexers were hot commodities in the early 2020s as experts predicted the platforms, which help clients build their own, personalized indexes that come with significant tax advantages, could even take over the ETF industry itself? The laundry list of proud new index shop owners included BlackRock, Charles Schwab, Morgan Stanley and JPMorgan, to name just a few. '[Acquisitions] are not easy, no matter which seat you are in,' DeMaso said. 'But this has not been a win-win coming together. Said differently, Vanguard is 0 for 1 on acquisitions … at least from the viewpoint of the acquired.' This post first appeared on The Daily Upside. To receive financial advisor news, market insights, and practice management essentials, subscribe to our free Advisor Upside newsletter. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 9627149Webcast: Available on the events section of the Ocugen investor site A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site. About Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen's modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at and follow us on X and LinkedIn. Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled 'Risk Factors' in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release. Contact:Tiffany HamiltonAVP, Head of
Yahoo
6 days ago
- Business
- Yahoo
Vishay Precision Group Announces Date for Its Second Quarter Fiscal 2025 Earnings Conference Call
MALVERN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, will release its financial results for the second quarter fiscal 2025 before the opening of the market on Tuesday, August 5, 2025. Ziv Shoshani, chief executive officer, and Bill Clancy, chief financial officer, will host a conference call that day (Tuesday, August 5, 2025) at 9:00 a.m. U.S. eastern time. To access the conference call, interested parties should call 1-833-470-1428 or internationally +1-404-975-4839 and use passcode 010019, or may access the live webcast by visiting the 'Events' page of investor relations section of the VPG website at A webcast replay will be available for a limited time approximately one hour after the completion of the call by dialing toll-free 1-866-813-9403 or internationally +1-929-458-6194 and by using passcode 958597. The replay will also be available on the 'Events' page of investor relations section of the VPG website at for a limited time. About VPGVishay Precision Group, Inc. (VPG) is a leader in precision measurement and sensing technologies. Our sensors, weighing solutions and measurement systems optimize and enhance our customers' product performance across a broad array of markets to make our world safer, smarter, and more productive. To learn more, visit VPG at and follow us on LinkedIn. Contact:Steve CantorSr. Director, Investor RelationsVishay Precision Groupinfo@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
6 days ago
- Business
- Globe and Mail
Vishay Precision Group Announces Date for Its Second Quarter Fiscal 2025 Earnings Conference Call
MALVERN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, will release its financial results for the second quarter fiscal 2025 before the opening of the market on Tuesday, August 5, 2025. Ziv Shoshani, chief executive officer, and Bill Clancy, chief financial officer, will host a conference call that day (Tuesday, August 5, 2025) at 9:00 a.m. U.S. eastern time. To access the conference call, interested parties should call 1-833-470-1428 or internationally +1-404-975-4839 and use passcode 010019, or may access the live webcast by visiting the 'Events' page of investor relations section of the VPG website at A webcast replay will be available for a limited time approximately one hour after the completion of the call by dialing toll-free 1-866-813-9403 or internationally +1-929-458-6194 and by using passcode 958597. The replay will also be available on the 'Events' page of investor relations section of the VPG website at for a limited time. About VPG Vishay Precision Group, Inc. (VPG) is a leader in precision measurement and sensing technologies. Our sensors, weighing solutions and measurement systems optimize and enhance our customers' product performance across a broad array of markets to make our world safer, smarter, and more productive. To learn more, visit VPG at and follow us on LinkedIn.
